#SK Biopharmaceuticals RPT Phase 1 FDA

Total 1 articles

Interior view of SK Biopharmaceuticals radiopharmaceutical research lab

SK Biopharmaceuticals RPT Drug Candidate SKL35501 Wins US FDA Phase 1 Approval

SK Biopharmaceuticals has secured US FDA Phase 1 clearance for its RPT drug candidate SKL35501. It's the first Korean firm to enter alpha-emitter RPT trials in the US.

Jan 12, 2026